News >

Lurbinectedin Does Not Improve PFS in Platinum-Resistant Ovarian Cancer

Wayne Kuznar
Published: Monday, Nov 12, 2018

Stephanie Gaillard, MD

Stephanie Gaillard, MD

Results of the phase III CORAIL trial demonstrated that the marine-derived treatment lurbinectedin did not improve progression-free survival (PFS) compared with pegylated liposomal doxorubicin (PLD) or topotecan in patients with platinum-resistant ovarian cancer.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication